Peter Finnie

Peter works with a long and growing list of European start-up companies, advising them on how to develop their IP strategies in a way that will build and support exit value.

He also makes sure their IP plays the part that it should within both business planning and fund raising. He has helped many of his clients successfully navigate a course through a series of funding rounds. He also sits on a number of boards for his clients so they can take full advantage of his broader commercial experience. 

Building on his reputation as a leading IP strategist in the IAM Strategy 300, Peter has developed a suite of IP consultancy products addressing the need for innovation capture, IP audit and commercial strategy development for technology companies seeking private equity funding. Likewise, he has developed IP due diligence products for investors designed to evaluate and test the strength of a business’s IP. His approach provides investors with a pragmatic and cost-effective way to evaluate the IP risks associated with technology investments to ensure they get the right deal. 

Peter regularly writes on the subject of IP strategy development and implementation in technology magazines such as SmallBusiness.co.uk, NS Tech and UKTN, and he has been published in the scientific journal Drug Discovery Today on the use of artificial intelligence in drug repurposing. 

Peter has considerable experience before the UK Intellectual Property Office and European Patent Office handling complex cases relating to the protection of computer-implemented inventions. He handles high-value standards-essential patents in the telecommunications field and routinely appears before the EPO and UK IPO at oral proceedings.